

10/667,183

=> file caplus

FILE 'CAPLUS' ENTERED AT 14:30:24 ON 28 OCT 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.


FILE COVERS 1907 - 28 Oct 2004 VOL 141 ISS 18

FILE LAST UPDATED: 27 Oct 2004 (20041027/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d que

L1 STR



Structure attributes must be viewed using STN Express query preparation.

L3 22 SEA FILE=REGISTRY SSS FUL L1

L4 3 SEA FILE=CAPLUS L3

=> d l4 1-3 ibib abs hitstr

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2004:346231 CAPLUS

DOCUMENT NUMBER: 141:71490

TITLE: Synthesis and biological evaluation of novel 2-pyridinyl-[1,2,3]triazoles as inhibitors of transforming growth factor  $\beta$ 1 type 1 receptor

AUTHOR(S): Kim, Dae-Kee; Kim, Joonseop; Park, Hyun-Ju

CORPORATE SOURCE: College of Pharmacy, Ewha Womans University, 11-1 Daehyun-dong, Seodaemun-gu, Seoul, 120-750, S. Korea

SOURCE: Bioorganic & Medicinal Chemistry Letters (2004), 14(10), 2401-2405

CODEN: BMCLE8; ISSN: 0960-894X


PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 141:71490

GI



AB A series of 2-pyridinyl-[1,2,3]triazoles have been synthesized and evaluated for their ALK5 inhibitory activity in the luciferase reporter assays. Quinoxalinyl-substituted 2-pyridinyl-[1,2,3]triazole I showed significant ALK5 inhibition (SBE-luciferase activity, 25%; p3TP-luciferase activity, 17%) at a concentration of 5  $\mu$ M that is comparable to that of SB-431542 (SBE-luciferase activity, 21%; p3TP-luciferase activity, 12%), but weak p38 $\alpha$  MAP kinase inhibition (13%) at a concentration of 10  $\mu$ M that is much lower than that of SB-431542 (54%).


IT 710946-96-6P 710946-97-7P 710946-98-8P  
710946-99-9P 710947-08-3P 710947-09-4P  
710947-10-7P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 2-pyridinyl-[1,2,3]triazoles as inhibitors of transforming growth factor  $\beta$ 1 type 1 receptor)

RN 710946-96-6 CAPLUS


CN Benzonitrile, 4-[[4-(1,3-benzodioxol-5-yl)-5-(2-pyridinyl)-2H-1,2,3-triazol-2-yl]methyl]- (9CI) (CA INDEX NAME)



RN 710946-97-7 CAPLUS


CN Benzonitrile, 4-[[4-(1,3-benzodioxol-5-yl)-5-(6-methyl-2-pyridinyl)-2H-1,2,3-triazol-2-yl]methyl]- (9CI) (CA INDEX NAME)

10/667,183




RN 710946-98-8 CAPLUS

CN Benzonitrile, 4-[[4-(2-pyridinyl)-5-(6-quinoxaliny)-2H-1,2,3-triazol-2-yl]methyl]- (9CI) (CA INDEX NAME)




RN 710946-99-9 CAPLUS

CN Benzonitrile, 4-[[4-(6-methyl-2-pyridinyl)-5-(6-quinoxaliny)-2H-1,2,3-triazol-2-yl]methyl]- (9CI) (CA INDEX NAME)



RN 710947-08-3 CAPLUS


CN Benzonitrile, 4-[4-(1,3-benzodioxol-5-yl)-5-(2-pyridinyl)-2H-1,2,3-triazol-2-yl]- (9CI) (CA INDEX NAME)



10/667,183


RN 710947-09-4 CAPLUS

CN Benzonitrile, 4-[4-(1,3-benzodioxol-5-yl)-5-(6-methyl-2-pyridinyl)-2H-1,2,3-triazol-2-yl]- (9CI) (CA INDEX NAME)



RN 710947-10-7 CAPLUS

CN Benzonitrile, 4-[4-(6-methyl-2-pyridinyl)-5-(6-quinoxaliny)-2H-1,2,3-triazol-2-yl]- (9CI) (CA INDEX NAME)



IT 710947-02-7P 710947-03-8P 710947-04-9P

710947-05-0P 710947-13-0P 710947-14-1P


710947-15-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation of 2-pyridinyl-[1,2,3]triazoles as inhibitors of transforming growth factor  $\beta$ 1 type 1 receptor)

RN 710947-02-7 CAPLUS


CN Benzamide, 4-[[4-(1,3-benzodioxol-5-yl)-5-(2-pyridinyl)-2H-1,2,3-triazol-2-yl]methyl]- (9CI) (CA INDEX NAME)



RN 710947-03-8 CAPLUS


CN Benzamide, 4-[[4-(1,3-benzodioxol-5-yl)-5-(6-methyl-2-pyridinyl)-2H-1,2,3-triazol-2-yl]methyl]- (9CI) (CA INDEX NAME)

10/667,183




RN 710947-04-9 CAPLUS

CN Benzamide, 4-[[4-(2-pyridinyl)-5-(6-quinoxaliny)-2H-1,2,3-triazol-2-yl]methyl]- (9CI) (CA INDEX NAME)



RN 710947-05-0 CAPLUS


CN Benzamide, 4-[[4-(6-methyl-2-pyridinyl)-5-(6-quinoxaliny)-2H-1,2,3-triazol-2-yl]methyl]- (9CI) (CA INDEX NAME)




RN 710947-13-0 CAPLUS

CN Benzamide, 4-[4-(1,3-benzodioxol-5-yl)-5-(2-pyridinyl)-2H-1,2,3-triazol-2-yl]- (9CI) (CA INDEX NAME)


10/667,183



RN 710947-14-1 CAPLUS  
CN Benzamide, 4-[4-(1,3-benzodioxol-5-yl)-5-(6-methyl-2-pyridinyl)-2H-1,2,3-triazol-2-yl]- (9CI) (CA INDEX NAME)




RN 710947-15-2 CAPLUS  
CN Benzamide, 4-[4-(6-methyl-2-pyridinyl)-5-(6-quinoxaliny)-2H-1,2,3-triazol-2-yl]- (9CI) (CA INDEX NAME)




IT 710946-91-1P 710946-92-2P 710946-93-3P  
710946-94-4P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of 2-pyridinyl-[1,2,3]triazoles as inhibitors of transforming growth factor  $\beta$ 1 type 1 receptor)  
RN 710946-91-1 CAPLUS  
CN Pyridine, 2-[5-(1,3-benzodioxol-5-yl)-2H-1,2,3-triazol-4-yl]- (9CI) (CA INDEX NAME)


10/667,183




RN 710946-92-2 CAPLUS  
CN Pyridine, 2-[5-(1,3-benzodioxol-5-yl)-2H-1,2,3-triazol-4-yl]-6-methyl-  
(9CI) (CA INDEX NAME)



RN 710946-93-3 CAPLUS  
CN Quinoxaline, 6-[5-(2-pyridinyl)-2H-1,2,3-triazol-4-yl]- (9CI) (CA INDEX  
NAME)



RN 710946-94-4 CAPLUS  
CN Quinoxaline, 6-[5-(6-methyl-2-pyridinyl)-2H-1,2,3-triazol-4-yl]- (9CI)  
(CA INDEX NAME)



REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/667,183

ACCESSION NUMBER: 2004:267243 CAPLUS  
DOCUMENT NUMBER: 140:287414  
TITLE: Preparation of 2-(triazolyl)pyridines and related compounds as transforming growth factor (TGF) inhibitors for the treatment of cancer and fibrotic diseases.  
INVENTOR(S): Blumberg, Laura Cook; Munchhof, Michael John  
PATENT ASSIGNEE(S): Pfizer Products Inc., USA  
SOURCE: PCT Int. Appl., 47 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004026307	A1	20040401	WO 2003-IB3825	20030908
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004110798	A1	20040610	US 2003-667183	20030917
PRIORITY APPLN. INFO.:			US 2002-412079P	P 20020918
			US 2003-484535P	P 20030702
OTHER SOURCE(S):		MARPAT 140:287414		
GI				

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Title compds. I, II and III [R1 = (un)saturated aromatic, monocyclic, bicyclic, etc.; R2 = (R3)s; R3 = H, halo, halo-alkyl, etc.; s = 1-5; R4 = H, halo, alkenyl, etc.] and their pharmaceutically acceptable salts were prepared For example, [3+2] cycloaddn. of azidotrimethylsilane to alkyne IV e.g., prepared from 6-bromo-3-methyl-1,2,4-triazolo[4,3-a]pyridine in 3-steps, afforded triazole V in 39% yield. In  $\beta$ 1-transforming growth factors kinase assay, triazole V exhibited an IC50 value of 58 nM. Of note, triazoles I, II and III also possess differential activity, i.e. are selective for  $\beta$ 1-TGF over  $\beta$ 2-TGF and  $\beta$ 3-TGF. Compds. I, II and III are claimed useful for the treatment of TGF-related disease states including cancer and fibrotic diseases.

IT **676169-95-2P**, 6-[5-(6-Methylpyridin-2-yl)-2H-[1,2,3]triazol-4-yl]quinazoline


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 2-(triazolyl)pyridines and related compds. as transforming growth factor (TGF) inhibitors for the treatment of cancer and fibrotic diseases.)

RN 676169-95-2 CAPLUS

CN Quinazoline, 6-[5-(6-methyl-2-pyridinyl)-2H-1,2,3-triazol-4-yl]- (9CI)  
(CA INDEX NAME)

10/667,183



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:391710 CAPLUS

DOCUMENT NUMBER: 136:401764

TITLE: Preparation of pyridyl-substituted triazoles as TGF inhibitors

INVENTOR(S): Gaster, Laramie Mary; Harling, John David; Heer, Jag Paul; Heightman, Thomas Daniel; Payne, Andrew Hele

PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA

SOURCE: PCT Int. Appl., 28 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002040476	A1	20020523	WO 2001-GB5036	20011115
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2002014163	A5	20020527	AU 2002-14163	20011115
EP 1335916	A1	20030820	EP 2001-982621	20011115
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2004517069	T2	20040610	JP 2002-543486	20011115
US 2004152738	A1	20040805	US 2004-416680	20040322
PRIORITY APPLN. INFO.:			GB 2000-27987	A 20001116
			WO 2001-GB5036	W 20011115

OTHER SOURCE(S): MARPAT 136:401764

GI



AB The title compds. [I; R1 = (un)substituted naphthyl, Ph, or Ph fused with an aromatic or non-aromatic cyclic ring of 5-7 members wherein said cyclic ring optionally contains up to three heteroatoms, independently selected from N, O and S, and N; R2 = H, alkyl, alkoxy, etc.; two of X1-X3 = N and the other is NR3 (wherein R3 = H, alkyl, cycloalkyl, etc.)] and their pharmaceutically acceptable salts, useful for the treatment of a disease mediated by the ALK5 receptor in mammals, were prepared. Thus, treatment of 5-(6-methylpyridin-2-ylethynyl)-benzo[1,2,5]thiadiazole (preparation given) with TMSN3 afforded 75% II. The compds. I generally show ALK5 receptor modulator activity having IC50 of 0.0001-10  $\mu$ M.


IT 428817-38-3P 428817-43-0P 428817-44-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyridyl-substituted triazoles as TGF inhibitors)


RN 428817-38-3 CAPLUS

CN 2,1,3-Benzothiadiazole, 5-[2-ethyl-5-(6-methyl-2-pyridinyl)-2H-1,2,3-triazol-4-yl]- (9CI) (CA INDEX NAME)



RN 428817-43-0 CAPLUS


CN [1,2,4]Triazolo[1,5-a]pyridine, 6-[2-ethyl-5-(6-methyl-2-pyridinyl)-2H-1,2,3-triazol-4-yl]- (9CI) (CA INDEX NAME)



10/667,183

RN 428817-44-1 CAPLUS

CN [1,2,4]Triazolo[1,5-a]pyridine, 6-[2-methyl-5-(6-methyl-2-pyridinyl)-2H-1,2,3-triazol-4-yl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> => file uspatall

FILE 'USPATFULL' ENTERED AT 14:31:10 ON 28 OCT 2004


CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 14:31:10 ON 28 OCT 2004

CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

=> d que

L1 STR



Structure attributes must be viewed using STN Express query preparation.

L3 22 SEA FILE=REGISTRY SSS FUL L1

L5 2 SEA L3

=> d l5 1-2 ibib abs hitstr

L5 ANSWER 1 OF 2 USPATFULL on STN

ACCESSION NUMBER: 2004:197432 USPATFULL

TITLE: Pyridyl-substituted triazoles as tgf inhibitors

INVENTOR(S): Gaster, Laramie Mary, Harlow Essex, UNITED KINGDOM

Harling, John David, Harlow Essex, UNITED KINGDOM

Heer, Jag Paul, Harlow Essex, UNITED KINGDOM

Heightman, Thomas Daniel, Harlow Essex, UNITED KINGDOM

Payne, Andrew Hele, Harlow Essex, UNITED KINGDOM

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004152738	A1	20040805
APPLICATION INFO.:	US 2004-416680	A1	20040322 (10)
	WO 2001-GB5036		20011115

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2000-27987	20001116

10/667,183

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: SMITHKLINE BEECHAM CORPORATION, CORPORATE INTELLECTUAL  
PROPERTY-US, UW2220, P. O. BOX 1539, KING OF PRUSSIA,  
PA, 19406-0939

NUMBER OF CLAIMS: 12  
EXEMPLARY CLAIM: 1  
LINE COUNT: 935

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Pyridyl substituted triazoles of formula (I) ##STR1##

wherein R.sub.1 is naphthyl or phenyl optionally substituted with one or more substituents selected from the group consisting of halo, --O--C.sub.1-6alkyl, --S--C.sub.1-6alkyl, C.sub.1-6alkyl, C.sub.1-6haloalkyl, --O--(CH.sub.2).sub.n-Ph, --S--(CH.sub.2).sub.n-Ph, cyano, phenyl, and CO.sub.2R, wherein R is hydrogen or C.sub.1-6alkyl, and n is 0, 1, 2 or 3; or R.sub.1 is phenyl fused with an aromatic or non-aromatic cyclic ring of 5-7 members wherein said cyclic ring optionally contains up to three heteroatoms, independently selected from N, O and S, and N may be further optionally substituted by C.sub.1-6 alkyl;

R.sub.2 is H, C.sub.1-6alkyl, C.sub.1-6alkoxy, phenyl, NH(CH.sub.2).sub.n-Ph, NH--C.sub.1-6alkyl, halo, CN, NO.sub.2, CONHR and SO.sub.2NHR;

two of X.sub.1, X.sub.2 and X.sub.3 are N and the other is NR.sub.3 wherein R.sub.3 is hydrogen, C.sub.1-6alkyl, C.sub.3-7cycloalkyl, --(CH.sub.2).sub.p--CN, --(CH.sub.2).sub.p--CO.sub.2H, --(CH.sub.2).sub.p--CONHR.sub.4R.sub.5, --(CH.sub.2).sub.pCOR.sub.4, --(CH.sub.2).sub.q(OR.sub.6).sub.2, --(CH.sub.2).sub.pOR.sub.4, --(CH.sub.2).sub.q--CH.dbd.CH--CN, --(CH.sub.2).sub.q--CH.dbd.CH--CO.sub.2H, --(CH.sub.2).sub.p--CH.dbd.CH--CONHR.sub.4R.sub.5, (CH.sub.2).sub.pNHCOR.sub.7 or (CH.sub.2).sub.pNR.sub.8R.sub.9;

R.sub.4 and R.sub.5 are independently hydrogen or C.sub.1-6alkyl;

R.sub.6 is C.sub.1-6alkyl;

R.sub.7 is C.sub.1-7alkyl, or optionally substituted aryl, heteroaryl, arylC.sub.1-6alkyl or heteroarylC.sub.1-6alkyl;

R.sub.8 and R.sub.9 are independently selected from hydrogen, C.sub.1-6alkyl, aryl and arylC.sub.1-6alkyl;

p is 04; and

q is 1-4.

and salts and solvates thereof, are disclosed, as are methods for their preparation, pharmaceutical compositions containing them and their use in medicine.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 428817-38-3P 428817-43-0P 428817-44-1P

(preparation of pyridyl-substituted triazoles as TGF inhibitors)

RN 428817-38-3 USPATFULL


CN 2,1,3-Benzothiadiazole, 5-[2-ethyl-5-(6-methyl-2-pyridinyl)-2H-1,2,3-triazol-4-yl]- (9CI) (CA INDEX NAME)

10/667,183




RN 428817-43-0 USPATFULL

CN [1,2,4]Triazolo[1,5-a]pyridine, 6-[2-ethyl-5-(6-methyl-2-pyridinyl)-2H-1,2,3-triazol-4-yl]- (9CI) (CA INDEX NAME)



RN 428817-44-1 USPATFULL

CN [1,2,4]Triazolo[1,5-a]pyridine, 6-[2-methyl-5-(6-methyl-2-pyridinyl)-2H-1,2,3-triazol-4-yl]- (9CI) (CA INDEX NAME)



L5 ANSWER 2 OF 2 USPATFULL on STN

ACCESSION NUMBER: 2004:145125 USPATFULL

TITLE: Novel triazole compounds as transforming growth factors (TGF) inhibitors

INVENTOR(S): Munchhof, Michael J., Salem, CT, UNITED STATES

Blumberg, Laura C., Waterford, CT, UNITED STATES

PATENT ASSIGNEE(S): Pfizer Inc (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004110798	A1	20040610
APPLICATION INFO.:	US 2003-667183	A1	20030917 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-412079P	20020918 (60)
	US 2003-484535P	20030702 (60)

10/667,183

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: PFIZER INC., PATENT DEPARTMENT, MS8260-1611, EASTERN  
POINT ROAD, GROTON, CT, 06340

NUMBER OF CLAIMS: 12  
EXEMPLARY CLAIM: 1  
LINE COUNT: 1149

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB Novel triazole compounds, including derivatives thereof, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use are described. The compounds of the present invention are potent inhibitors of transforming growth factor ("TGF")- $\beta$  signaling pathway. They are useful in the treatment of various TGF-related disease states including, for example, cancer and fibrotic diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 676169-95-2P, 6-[5-(6-Methylpyridin-2-yl)-2H-[1,2,3]triazol-4-yl]quinazoline  
(preparation of 2-(triazolyl)pyridines and related compds. as transforming growth factor (TGF) inhibitors for the treatment of cancer and fibrotic diseases.)

RN 676169-95-2 USPATFULL

CN Quinazoline, 6-[5-(6-methyl-2-pyridinyl)-2H-1,2,3-triazol-4-yl]- (9CI)  
(CA INDEX NAME)



=>